Poseida Therapeutics, Inc.
4250 Campus Point Court
19 articles with Poseida Therapeutics, Inc.
Be The Match BioTherapies® Announces Collaboration with Poseida Therapeutics to Support Development of Life-Saving Cellular Therapies
Be The Match BioTherapies will provide end-to-end support services to accelerate clinical development of Poseida’s autologous BCMA and PSMA CAR-T programs
Malin Corporation plc: Poseida receives FDA orphan drug designation for lead candidate and FDA approval of fully outpatient dosing in Phase 2 clinical trial
Malin Corporation plc. (Euronext Growth Dublin:MLC) (“Malin”), a company investing in highly innovative life sciences companies, is pleased to note that Poseida Therapeutics Inc. (“Poseida”), one of Malin’s Priority Assets, has announced the US Food and Drug Administration (“FDA”) has granted orphan drug designation to P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma.
Rapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals
Rapha Capital Management, LLC, an investment management firm located in Miami, Florida, and their associated entities announced their participation in a Series C financing for Poseida Therapeutics.
Swiss pharma giant Novartis supported the company’s Series C financing round with a $75 million equity investment.
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
8/7/2018Teneobio, Inc., a next generation multi-specific antibody therapeutics company, and Poseida Therapeutics, Inc., a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving cell therapies, announced today a new research collaboration and licensi...
Dr. Giedlin brings significant expertise in cell therapy process development, manufacturing, and strategy in immunotherapies.
Poseida Therapeutics Announces First Patient Treated in Phase I Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients With Multiple Myeloma
The objective of the study is to evaluate the safety and efficacy of P-BCMA-101 in patients with relapsed/refractory multiple myeloma and determine a recommended Phase 2 dose.
Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting
The company announced preclinical data from multiple chimeric antigen receptor T cell (CAR-T) programs in Poseida’s drug development pipeline.
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting
The study was selected for oral presentation today at the American Association for Cancer Research Prostate Cancer: Advances in Basic, Translational, and Clinical Research meeting in Orlando, Florida.
Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit
The presentation expands on the anti-BCMA CAR-T development programs featuring Poseida’s proprietary piggyBac non-viral gene delivery system and Centyrin binding domain.
Poseida Awarded $19.8M CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma
P-BCMA-101 is a chimeric antigen receptor T cell (CAR-T) immunotherapy currently in a Phase 1 clinical trial as a treatment for relapsed and refractory multiple myeloma.
Poseida Therapeutics Presents Preclinical Solid Tumor Data For P-PSMA-101, A CAR-T Therapy Predominantly Comprised Of Stem Cell Memory T Cells, At The Prostate Cancer Foundation Annual Retreat
Poseida Therapeutics Opens Enrollment In A Phase I Study Of BCMA-Specific CAR-T Stem Cell Memory Therapy For Patients With Multiple Myeloma
Poseida Therapeutics Presents High-Fidelity Genome Editing System For Production Of Allogeneic "Universal Donor" CAR-T Cells At ASCO Annual Meeting
TeneoBio, Inc. And Poseida Therapeutics Announce License Agreement For The Use Of Unidab In CAR T-Cell Therapy